Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Original languageEnglish (US)
    Pages (from-to)2147-2148
    Number of pages2
    JournalJournal of Urology
    Volume188
    Issue number6
    DOIs
    StatePublished - Dec 2012

    ASJC Scopus subject areas

    • Urology

    Cite this